Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU):: The Phase 2 SATURN Study.

Author: AthanikarAditya, BuggageRonald, CallananDavid, ChengYenchieh, ChuKaren, Corp-Dit-GentiValerie, EricksonKristine, Garcia-GarciaOlga, HeissigerováJarmila, KadayifcilarSibel, KarkanováMichala, NguyenQuan Dong, OzyazganYilmaz, SarojNamrata, SooYuhwen, SrivastavaSunil K, SundaramPreethi A, VaronaRafael, VittiRobert, de SmetMarc D

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A phase 2 study found that subcutaneous sarilumab may be beneficial in managing noninfectious uveitis of the posterior segment, especially in eyes with uveitic macular edema. It led to a greater reduction in vitreous haze and improvement in visual acuity compared to placebo.
Paper Details　
Original Abstract of the Article :
PURPOSE: To assess efficacy and safety of sarilumab, a human anti-interleukin-6 receptor antibody, for treatment of posterior segment noninfectious uveitis (NIU). DESIGN: Randomized, double-masked, placebo-controlled, phase 2 study. PARTICIPANTS: Fifty-eight patients (eyes) with noninfectious inte...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ophtha.2018.09.044

データ提供：米国国立医学図書館（NLM）

Treating Uveitis with Sarilumab: A New Hope for the Posterior Segment

Noninfectious uveitis (NIU) is an inflammatory condition that affects the uvea, the middle layer of the eye. This study investigates the efficacy and safety of sarilumab, a human anti-interleukin-6 receptor antibody, for treating NIU of the posterior segment.

A Promise for a Brighter Vision: Sarilumab's Impact on Uveitis

The study found that sarilumab was associated with a greater reduction in vitreous haze (VH) and a greater improvement in best-corrected visual acuity compared to placebo, particularly for patients with severe VH at baseline and those with central subfield thickness (CST) ≥300 μm at baseline. These findings suggest that sarilumab may be an effective treatment option for NIU of the posterior segment.

A Ray of Hope for Uveitis Patients: The Benefits of Sarilumab

This study provides encouraging evidence that sarilumab may offer a new hope for patients with NIU of the posterior segment, especially those experiencing significant visual impairment. If you are diagnosed with NIU, discussing the potential benefits of sarilumab with your healthcare provider is essential. Together, you can develop a treatment plan that addresses your individual needs and helps you achieve better vision and overall health.

Dr.Camel's Conclusion

Imagine a desert landscape, vast and breathtaking, but with a blurry horizon. Sarilumab, like a magical lens, helps to sharpen that vision, offering hope for those with NIU of the posterior segment. This research opens a new chapter in the fight against uveitis, providing promising insights into the potential for improved vision and quality of life for those affected by this condition.

Date :
  1. Date Completed 2020-01-03
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

30316888

DOI: Digital Object Identifier

10.1016/j.ophtha.2018.09.044

Related Literature

Article Analysis
・Effects of sarilumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.